Expert consensus: main risk factors for poor prognosis in COVID-19 and the implications for targeted measures against SARS-CoV-2
FJ Candel, P Barreiro, M Salavert, A Cabello… - Viruses, 2023 - mdpi.com
The clinical evolution of patients infected with the Severe Acute Respiratory Coronavirus
type 2 (SARS-CoV-2) depends on the complex interplay between viral and host factors. The …
type 2 (SARS-CoV-2) depends on the complex interplay between viral and host factors. The …
SARS-CoV-2 vaccination in solid-organ transplant recipients
M Peghin, E Graziano, PA Grossi - Vaccines, 2022 - mdpi.com
The coronavirus disease 2019 (COVID-19) pandemic has posed significant global
challenges for solid organ transplant (SOT) recipients. Mortality rates of COVID-19 in this …
challenges for solid organ transplant (SOT) recipients. Mortality rates of COVID-19 in this …
[HTML][HTML] Incidence and severity of SARS-CoV-2 infections in liver and kidney transplant recipients in the post-vaccination era: Real-life data from Denmark
SR Hamm, O Rezahosseini, DL Møller, JA Loft… - American Journal of …, 2022 - Elsevier
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has been associated with a
high risk of adverse outcomes in solid organ transplant (SOT) recipients in the pre …
high risk of adverse outcomes in solid organ transplant (SOT) recipients in the pre …
Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV–a prospective …
LD Heftdal, L Pérez-Alós, RB Hasselbalch… - …, 2023 - thelancet.com
Background We investigated long-term durability of humoral and cellular immune responses
to third dose of BNT162b2 in people with HIV (PWH) and controls. Methods In 378 PWH with …
to third dose of BNT162b2 in people with HIV (PWH) and controls. Methods In 378 PWH with …
Humoral response to SARS-CoV-2 mRNA vaccination in previous non-responder kidney transplant recipients after short-term withdrawal of mycophenolic acid
L Benning, C Morath, T Kühn, M Bartenschlager… - Frontiers in …, 2022 - frontiersin.org
Seroconversion rates after COVID-19 vaccination are significantly lower in kidney transplant
recipients compared to healthy cohorts. Adaptive immunization strategies are needed to …
recipients compared to healthy cohorts. Adaptive immunization strategies are needed to …
Humoral and T-cell response 12 months after the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics, associated factors, and role of …
O Rezahosseini, SR Hamm, LD Heftdal… - Frontiers in …, 2023 - frontiersin.org
Introduction We investigated humoral and T-cell responses within 12 months after first
BNT162b2 vaccine in solid organ transplant (SOT) recipients and controls who had received …
BNT162b2 vaccine in solid organ transplant (SOT) recipients and controls who had received …
Reduced antibody acquisition with increasing age following vaccination with BNT162b2: results from two longitudinal cohort studies in the Netherlands
LL van den Hoogen, M Boer, A Postema, L de Rond… - Vaccines, 2022 - mdpi.com
Vaccine-induced protection against severe COVID-19, hospitalization, and death is of the
utmost importance, especially in the elderly. However, limited data are available on humoral …
utmost importance, especially in the elderly. However, limited data are available on humoral …
Risk of severe COVID-19 and protective effectiveness of vaccination among solid organ transplant recipients
K Huh, M Kang, YE Kim, Y Choi, SJ An… - The Journal of …, 2024 - academic.oup.com
Background Solid organ transplant recipients (SOTRs) are at higher risk for severe infection.
However, the risk for severe COVID-19 and vaccine effectiveness among SOTRs remain …
However, the risk for severe COVID-19 and vaccine effectiveness among SOTRs remain …
SARS-CoV-2 infection risk is higher in vaccinated patients with inflammatory autoimmune diseases or liver transplantation treated with mycophenolate due to an …
M Rizzi, S Tonello, C Brinno, E Zecca… - Frontiers in …, 2023 - frontiersin.org
Background A relevant proportion of immunocompromised patients did not reach a
detectable seroconversion after a full primary vaccination cycle against SARS-CoV-2. The …
detectable seroconversion after a full primary vaccination cycle against SARS-CoV-2. The …
[HTML][HTML] Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis
S Holm-Yildiz, T Dysgaard, T Krag, BS Pedersen… - Journal of …, 2023 - Elsevier
We investigated the humoral response to the Pfizer-BioNTech COVID-19 (BNT162b2)
vaccine in patients with myasthenia gravis on or off immunosuppressants and compared this …
vaccine in patients with myasthenia gravis on or off immunosuppressants and compared this …